In @entity1 with @entity4616 ( @entity4616 ) and cryptogenic @entity64 , observational studies have demonstrated reductions in recurrent neurologic events with transcatheter @entity22105 closure compared with medical therapy. Randomized controlled trials and meta-analyses have shown a trend toward benefit with device closure. The cost-effectiveness of @entity22105 closure has not been described. Therefore, a detailed cost analysis was performed using pooled weighted outcome and complication rates from published randomized controlled trials, Medicare cost tables, and wholesale medication prices. Incremental cost per life-year gained and per quality-adjusted life-year (QALY) gained by @entity22105 closure was calculated. The commonly accepted cost-effectiveness threshold of < 50,000/quality-adjusted life-year gained was used. At 2.6  years (the mean duration of randomized controlled trial follow-up), @entity22105 closure was more costly ( 16,213, 95% confidence interval [CI]  15,753 to  16,749) per @entity1 , with a cost of  103,607 (95% CI  5,826 to  2,544,750) per life-year gained. The expenditure to prevent 1 combined end point (transient @entity63 attack, @entity64 , and @entity204 ) at 2.6  years was  1.09 million (95% CI  1.04 million to  1.20 million). Modeling the costs of medical treatment prospectively, @entity22105 closure reached cost-effectiveness (< 50,000/quality-adjusted life-year gained) at 2.6 years (95% CI 1.5 to 44.2). At 30.2  years (95% CI 28.2 to 36.2), the per @entity1 mean cost of medical therapy exceeded that of @entity22105 closure. In conclusion, @entity22105 closure is associated with higher expenditures related to procedural costs; however, this increase may be offset over time by reduced event rates and costs of long-term medical treatment in @entity1 who undergo transcatheter @entity22105 closure. In younger @entity1 typical of cryptogenic @entity64 , @entity22105 closure may be cost effective in the long term.

Cost Effectiveness of Percutaneous Closure Versus Medical Therapy for Cryptogenic XXXX in @entity1 With a Patent Foramen Ovale.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity22105 :: ('CHEBI:60590', 'Chemical') :: ['PFO'] @entity4616 :: ('MESH:D054092', 'Disease') :: ['patent foramen ovales', 'PFOs'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity64 :: (MESH:D020521,Disease) :: ['Stroke']
